Shots:

• The P-III ECZTRA 6 trial evaluates the efficacy & safety of tralokinumab (150/300mg- q2w) as monothx. vs PBO in 301 patients aged 12-17yrs. with mod. to sev. AD who were candidates for systemic therapy
• The trial met its 1EPs & 2EPs i.e.- @16wks.- patients achieved a clinical response & achieved clear or almost clear skin as measured by IGA (21.4%/17.5% vs 4.3%); ≥75% disease improvement from baseline (28.6%/27.8% vs 6.4%) as measured by EASI
• In 2EPs- patients achieved 4-point improvement in adolescent weekly average worst daily pruritus NRS score & health-related QoL related to dermatological conditions. The therapy was well-tolerated with an overall frequency & severity of AEs

 ­ | Ref: Businesswire | Image: Berlingske